Sunesis Pharmaceuticals, Inc.  

(Public, NASDAQ:SNSS)   Watch this stock  
Find more results for SNSS
-0.003 (-0.44%)
Real-time:   1:20PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.68 - 0.72
52 week 0.65 - 3.72
Open 0.71
Vol / Avg. 77,449.00/199,494.00
Mkt cap 56.42M
P/E     -
Div/yield     -
EPS -0.37
Shares 85.03M
Beta 2.32
Inst. own 63%
Mar 10, 2016
Q4 2015 Sunesis Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1027.96% -749.95%
Operating margin -1254.76% -785.54%
EBITD margin - -785.04%
Return on average assets -78.16% -101.45%
Return on average equity -192.63% -1128.96%
Employees 39 -
CDP Score - -


Suite 400 395 Oyster Point Boulevard
United States - Map
+1-650-2663500 (Phone)
+1-650-2663501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company's program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD, which is used for the treatment of cancer. MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Officers and directors

Daniel N. Swisher Jr. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Eric H. Bjerkholt Chief Financial Officer, Executive Vice President - Corporate Development and Finance
Age: 55
Bio & Compensation  - Reuters
Adam R. Craig M.D, Ph.D. Executive Vice President - Development, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
James W. Young Ph.D. Non-Executive Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. Director
Age: 50
Bio & Compensation  - Reuters
Steve R. Carchedi Independent Director
Age: 53
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
Helen S. Kim Independent Director
Age: 52
Bio & Compensation  - Reuters